Company
Orthocell Ltd
ASX:OCC
Orthocell develops, manufactures and exports novel regenerative medicine products around the world. Its biological medical devices and cellular therapies are used by leading surgeons to treat musculoskeletal injuries of nerve, tendon and cartilage, and dental bone defects. The clinical results, compelling.
127 stories · page 6 of 7
Orthocell completes CelGro study accelerating dental implant treatments
The positive data comes as Orthocell is active in partnering discussions and will support the company to gain traction in key markets.
Orthocell secures European patent for its tissue regeneration technology
Important addition to the company's current European and global IP portfolio.
Orthocell secures U.S. patent for unique tissue regeneration technology
Intellectual property for Orthocell’s Cell Factory concept is now granted in the U.S. and Europe.
Orthocell secures European patent for unique tissue repair technology
Recent regulatory approval issued by the FDA in the U.S along with approvals in the UK.
Orthocell secures European market authorisation for medical device
CelGro device plays a critical role in dental bone and soft tissue regeneration.
Orthocell's European regulatory approval may be on the horizon
The halt will remain in place until Friday 10th November 2017.
Orthocell treats first patient in clinical trial of its injection for shoulder injury
The trial is an important element of Orthocell’s product development and partnering strategy.
Orthocell granted European patent for tissue repair technology
The new patent strengthens Orthocell’s intellectual property position
Orthocell to reveal strategic collaboration
Orthocell (ASX:OCC) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Orthocell gets ready to raise
Orthocell (ASX:OCC) has been granted a trading halt by the ASX, pending details of a capital raising.